Glaxosmithkline | GSK - Fremdkapital





Fremdkapital Veränderung Datum
AbbVie USD 58.94B 4.03B 2025-12
Amgen USD 51.89B 1.88B 2026-03
AstraZeneca USD 25.96B 177M 2026-03
Aurora Cannabis CAD 33.2M 1.79M 2025-12
Bausch Health Companies USD 19.9B 720M 2026-03
Bristol-Myers Squibb USD 42.15B 698M 2026-03
Canopy Growth CAD 224.99M 1.34M 2025-12
Drreddys Laboratories INR 129.19M 1.84M 2025-12
Eli Lilly USD 39.37B 1.5B 2026-03
GlaxoSmithKline GBP 14.01B 696M 2026-03
Glaxosmithkline GBP 19.82B 203.13M 2025-12
J&J USD 37.53B 1.91B 2026-03
Merck USD 46.67B 77M 2026-03
Novartis USD 37.45B 7.86B 2026-03
Pacira USD 367.66M 4.53M 2026-03
Perrigo USD 3.62B 17.5M 2026-03
Pfizer USD 60.57B 1.08B 2026-03
Phibro Animal Health USD 597.68M 5.92M 2026-03
Prestige Brands USD 1.01B 40.28M 2026-03
Roche Holding CHF 27.43B 966M 2025-12
Sanofi EUR 13.84B 1.88B 2026-03
Supernus Pharmaceuticals USD 400.38M 21.13M 2022-03
Takeda JPY 4.37T 99.51B 2026-03
Teva Pharmaceutical Industries USD 14.02B 971M 2026-03
Zoetis USD 9.04B 3M 2026-03